Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Date:3/14/2012

including their significance and what they were intended to address, refine and assess; the FDA advisory committee meeting and the discussion on the NDA resubmission; the potential approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; lorcaserin's patent coverage; cost-containment efforts; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when anticipated; the EU application is subject to acceptance and confirmation by the EU regulatory agency that it is sufficient to permit a substantive review; the FDA may not complete its review of the lorcaserin application by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
3. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
4. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
5. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
7. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
9. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
10. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:7/1/2015)... New York, NY (PRWEB) , ... July 01, 2015 , ... ... around which DNA is wound, histones, remain constant in the brain, never changing after ... Sinai have discovered that histones are steadily replaced in brain cells throughout life – ...
(Date:7/1/2015)... PA (PRWEB) , ... July 01, 2015 , ... ... purist natural forms, such as organically raised chickens and eggs. Eating organic foods ... backyard chickens is cleaner and more environmentally friendly than production chicken farming. Choosing ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... enterprise of Hospital Corporation of America (HCA), as it further expands its Strategic ... today. , With this new partnership, OncLive’s editorial and marketing teams will ...
(Date:7/1/2015)... ... , ... Lisa Keys, the widow of U.S. Army Master Sergeant Bradley Keys, ... memory of her late husband and all of America’s fallen military and first responders. ... died during a Special Forces training exercise in December of 2012. The ‘Legacy 5K’ ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying the High-Cost ... was published July 1st and is available at: http://www.hcttf.org/resouces-tools . , The ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3
... NOAA-supported scientists from the Louisiana Universities Marine Consortium and Louisiana ... coast of Louisiana and Texas in the Gulf of Mexico ... researchers are predicting the area could measure a record 8,800 ... 2007, the dead zone was 7,903 square miles. The largest ...
... of Industry ... Standards, ... exchange, today announced it has received full,accreditation by The Electronic Healthcare ... peer,evaluation of an organization,s ability to perform at industry established,levels., ...
... Company (NYSE: PG ) confirmed previously announced sales and ... 2007/08. The company,continues to expect sales growth for the quarter ... with previous guidance and diluted,earnings per share of $0.76 to ... available. P&G is scheduled,to announce the final results for the ...
... PRUSSIA, Pa., July 15 HighPoint Solutions LLC,a ... that it,has been selected by one of the ... a Contract Analytics Reporting & Scorecard solution. This,project ... reports, scorecards and dashboards, resulting in a complete ...
... shown an association between certain past diagnostic radiation procedures ... a rare form of prostate cancer which affects about ... disease. , The study, the first of its kind ... from diagnostic procedures and the risk of prostate cancer, ...
... the University of Warwick have discovered diabetes could be a ... In a study led by Dr Saverio Stranges, Associate Professor ... at levels of oxidative stress in the body (a toxic ... levels of oxidative stress in people with coronary heart disease, ...
Cached Medicine News:Health News:NOAA and Louisiana scientists predict largest Gulf of Mexico 'dead zone' on record 2Health News:Availity Awarded Full EHNAC Accreditation 2Health News:Availity Awarded Full EHNAC Accreditation 3Health News:Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08 2Health News:Procter & Gamble Confirms Prior Sales and Earnings Guidance for Fourth Quarter 2007/08 3Health News:HighPoint Solutions to Develop Contract Analytics Solution for a Top Three Pharmaceutical Company 2Health News:Possible link found between X-rays and prostate cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: